Altis Labs’ AI software detected treatment benefit earlier in oncology trial

By detecting potential treatment failure at earlier time points, physicians will be able to amend a patient's treatment plan. By detecting potential treatment failure at earlier time points, physicians will be able to amend a patient's treatment plan. IPRO was used in J&J’s Phase III MAIRPOSA study. Credit: Roman Shashko / Shutterstock.com Altis Labs’ artificial intelligence (AI)-powered imaging endpoint has shown its ability to detect early, notable treatment effects more effectively than standard endpoints. In Johnson & Johnson’s Phase III MAIRPOSA study (NCT04487080), which investigated Rybrevant (amivantamab) and Lazcluze (Lazertinib) in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell…

Source: Medical Device Network